Shanghai Zhimeng Biopharmaceutical’s CB-06036 to treat hepatitis B: Likelihood of approval

In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.

CB-06036 Overview

CB06-036 is in development for the treatment of hepatitis B infection. It works by targeting Toll-like receptor 8 (TLR8). It is administered by the oral route.

Overview of Shanghai Zhimeng Biopharmaceuticals

Shanghai Zhimeng Biopharmaceutical Co., Ltd. is a biotechnology company focused on discovering and developing innovative therapies for the treatment of chronic hepatitis B virus infection and neurological diseases. The company is headquartered in China.

For complete information on CB-06036 drug-specific PTSR and LoA scores, purchase the report here.

Desde

The gold standard in business intelligence.

GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.

better understand the situation